Meeting
2017 ASCO Annual Meeting
Association of PD-L1 expression with tumor infiltrating immune cells and mutation burden in the high grade neuroendocrine carcinoma of the lung.
Authors
Hye Sook Kim
Myongji Hospital, Goyang, Republic of Korea
Hye Sook Kim , Ji-Youn Han
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Citation
J Clin Oncol 35, 2017 (suppl; abstr 8564)
DOI
10.1200/JCO.2017.35.15_suppl.8564
Abstract #
8564
Poster Bd #
300
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
First Author: Jacob J. Adashek
Poster
2021 ASCO Annual Meeting
Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.
First Author: Biagio Ricciuti
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Deleterious alterations of DNA damage response and repair (DDR) genes in association with clinical benefit to programmed cell death protein-1 (PD-1)/PD ligand 1 (PD-L1)-based therapy in esophageal squamous cell carcinoma (ESCC).
First Author: Jhe-Cyuan Guo
Poster
2019 ASCO Annual Meeting
Tumor mutation burden and PD-L1 expression in SDH/FH mutated solid tumors.
First Author: Leylah Drusbosky